Novo Nordisk Is Losing Its Lead To Eli Lilly In The Obesity Drug War. Here’s What Went Wrong.
Growth Stories With IBD · Investor's Business Daily
August 15, 202519m 19s
Audio is streamed directly from the publisher (pdst.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
On this episode of Growth Stories, we take a look at the escalating rivalry between Novo Nordisk and Eli Lilly and how the Danish drugmaker lost its grip on the weight-loss drug market.
Learn more about your ad choices. Visit megaphone.fm/adchoices